4 May 2021 - NICE has today announced that more people with the rare genetic disorder spinal muscular atrophy are to benefit from nusinersen sodium (Spinraza; Biogen) following a review of data collected as part of the Managed Access Agreement.
The review, involving Biogen, patient groups, clinicians, SMA REACH UK and NHS England and NHS Improvement, assessed whether new evidence that had become available would support a change in the MAA treatment eligibility criteria.
Specifically, it looked at whether people with type III spinal muscular atrophy who are unable to walk can benefit from nusinersen sodium and therefore should be included in the Managed Access Agreement.